Taken together, our data not only revealed the significant role of TEAD4 in promoting LAD progression and predicting clinical outcome but also distinguished miR6839‐3p mimics as a promising therapeutic direction. This evidence concerns the gene TEAD4 and leukocyte adhesion deficiency.